ESMO 2023

Preoperative checkpointinihition in ER+ disease

DATO-DX - where is it going?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

My highlights of ESMO23 in metastatic breast cancer

Highlights in eBC

5 year follow-up

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

Lu-PSMA leads forward

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

Early use of enzalutamide in advanced prostate cancer

Tarlatamab in SCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

My highlights from ESMO 2023

ALINA - immediate change of practice!

What was the most exciting news at ESMO23?

Anticipated updates and exciting new data for checkpointinhibitors

New and better biomarkers are needed!

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

Pembrolizumab solidifies as SOC in early-stage TNBC

Detailed view of nodal-negative patients

Preoperative checkpointinihition in ER+ disease

Immunoncology in eBC - triple negative and more?

New data on neoadjuvant immunotherapy

Highlights in eBC

ER-low corresponds diagnostically to ER-0 breast cancer

5 year follow-up

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

HR+ study with > 20 % PCR

MonarchE - trial update

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Ribociclib effective in all subtypes

Carry-over effects in monarchE confirmed

Consolidation of data in early HR+ and triple-negative breast cancer

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Negative EFS results from NeoTrip

Our guidelines are correct

Analysis of tumour microenvironment and immunophenotype in TNBC

My highlights of ESMO23 in early breast cancer

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Clinically relevant effect of pembro also in PCR

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

Nouvelles données sur l'immunothérapie néoadjuvante

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Punti salienti in eBC

New targets, new linker, new ADCs - much more to learn with new therapies!

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

How to organize a molecular tumorboards in breast cancer?

New ADC for metastatic breast cancer?

What was the most exciting news at ESMO23?

Improvement of therapy outcome by app-based patient education

Remarkable efficacies in patients with HER2+ mBC with brain metastases

HS20089 - a novel ADC is coming for TNBC

TROP2 expression as a potential mechanism of resistance in HER2+ patients

Dato-DXd - new player in advanced luminal disease

Fulvestran better than anastrozole, but no survival benefit

Duvalumab + Dato-DXd effective

T-DXd in HER2+ patients with brain metastases

Patient-centered molecular medicine - a new approach

Even more new generation ADCs in breast cancer?

Our guidelines are correct

DATO-DX - where is it going?

OP seems to be dispensable for super responders

Can surgery be spared following primary systemic therapy?

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Robust data from the monarchE

Benefit for SG even after intensive pretreatment

T-DXd - new standard of care for brain mets?

Improved oncological therapy with the smartphone

Highlights in mBC

My highlights of ESMO23 in metastatic breast cancer

New ADC in HR+ disease

Still on track for success in HER2-low MBC

ADC + Immunotherapy - the BEGONIA study paradigm

Abemaciclib remains consistent in 5-year follow-up

HER2DX in the PHERgain trial

TULIP: Trastuzumab duocarmazine without OS benefit

T-DXd also effective for brain metastases

Punti salienti in mBC

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

HER2DX en el estudio PHERgain

T-DXd - nowy standard postępowania w przerzutach do mózgu?

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

Lo studio BEGONIA nelle paziento con tumore triplo negativo

What is the future of immune therapy in prostate cancer?

Targeted therapy will move forward - but more robust data is needed.

Should we use zoledronic acid in all ADT patients?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Early use of enzalutamide in advanced prostate cancer

Big data and AI prediction tools

Negative data for pembrolizumab in mHSCPC & mCRPC

RADICALS RT: Trial and controversies

ENZA P:Trial and controversies

EMBARK - Quality of Life

PSMA FORE: Trial and controversies

Embark without fear

Lu-PSMA leads forward

PSMAfore unleashes urooncologic opportunity

Osteoprotection at mHSPC

IO therapy in metastatic prostate cancer.

EMBARK expands ENZA indication to PCa

Longterm toxicity of adjuvant RT after prostatectomy

Precision medicine at mCRCP

Immunotherapy in metastatic PCa

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

TITAN: ultra-low PSA = best prognosis

Combination of radioligand therapy with chemotherapy useful

Brave New World in mCRPC

CXCR2 inhibitor in PCa

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Salvage radiotherapy the new standard

CXCR2 hämmare och prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

Big Data och AI för prediktion vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

EMBARK och livskvalitet

Immunterapi vid prostatacancer

Part1: New standard of care in first line urothelial cancer?!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Amazing new data in bladder cancer

Chemo-IO establishes itself in the first-line treatment of bladder cancer

EV + Pembro as standard of care in first-line therapy of bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

When the history of ADC is written: Redefining first-line standard of care in mUC!

FGFR inhibitors: What is the best scenario for this family of compounds?

New SoC in firstline bladder cancer

The FGFR story in bladder cancer at ESMO23

DAD, DAD-IO

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Where does the future therapy go in renal cell carcinoma?

Important new treatment option but only for subset of patients?

Is de-escalating therapy ready for prime-time?

New 3rd line therapy for RCC

New mode of action in mRCC - ready for prime time?

Belzutifan in later lines of therapy

Kidney cancer highlights at ESMO23

Intermittent therapy also possible with TKIs

Belzutifan - whats next kidney cancer?

Clearing up non-clear cell RCC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Substantial improvement in local regional NSCLC

Scene is set for inductive immunotherapy

ALINA - immediate change of practice!

Big improvements in early stage and a subset of metatstic NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Circulating DNA in AEGEAN trial

ALINA - a new paradigm in operated NSCLC with ALK-fusion

My highlights from ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

I miei punti salienti di ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

ESMO2023-impact on everyday practice!

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

Practice changing results on exon 20 insertion mNSCLC

Changing treatment landscape in EGFR-mutated NSCLC

Amivantamab at progression? MARIPOSA-2 trial

Substantial improvement in rare alterations

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

MARIPOSA: Trial and controversies

Treatment sequences for EGFR-mutated Patients

TROPION-Lung01: positive development

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

NRG fusions: a new drugable target?

Amivantamab upfront? MARIPOSA trial

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Big improvements in early stage and a subset of metatstic NSCLC

LIBRETO - a positive study, but was it necessary?

Adagrasib + pembrolizumab in patients with KRASG12C mutation

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

MARIPOSA II: Trial and controversies

Does immunotherapy still have a place in EGFR-positive mNSCLC?

PAPILLON - bringing together therapy for the 1st line

Do ADCs have brain activity?

My highlights from ESMO 2023

Brain metastases – options to improve the systemic treatment

By unanimous decision and still the champion – docetaxel!

Amivantamab upfront? MARIPOSA trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Quelles séquences thérapeutiques pour les patients EGFR mutés

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

I miei punti salienti di ESMO 2023

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Amivantamab at progression? MARIPOSA-2 trial

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Impact of T-cell engagers in SCLC

New hope for patients with SCLC

A new option in relapsed SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Precision oncology in CUP

New data on sarkomas

First data on luveltamab in multiline treatment for endometrial cancer

PCO Therapeutics

New data on H&N Cancer

Evolution of the revolution - the RUBY trial

Update on gynaecological cancers